📊 BIAFW Key Takeaways
Investment Thesis
bioAffinity Technologies exhibits severe financial distress with collapsing revenues (-34.2% YoY), massive operating losses (-10.6M on 6.2M revenue), and negative cash flow (-9.4M FCF). The company is burning cash rapidly despite holding 6.4M in liquidity, with no clear path to profitability and deteriorating operational performance.
BIAFW Strengths
- Positive current ratio of 2.60x indicates short-term liquidity to fund operations
- Zero long-term debt reduces financial leverage risk
- Cash position of 6.4M provides runway for operations
BIAFW Risks
- Revenue declining sharply at -34.2% YoY indicating loss of market traction or customer base
- Negative free cash flow of -9.4M with burn rate unsustainable; cash will deplete in 6-8 quarters at current burn
- Gross margin of only 3.9% shows inability to achieve unit economics or scale efficiency
- Operating loss of -10.6M on 6.2M revenue demonstrates fundamental business model dysfunction
- No insider buying activity over 90 days suggests management lacks confidence in turnaround
- Net margin of -242% indicates company loses $2.42 for every dollar of revenue
Key Metrics to Watch
- Quarterly revenue trend and customer retention rates
- Operating cash flow trajectory and monthly burn rate
- Gross margin improvement and cost structure efficiency
- Cash runway remaining and path to cash flow breakeven
- Product pipeline and commercial traction metrics
BIAFW Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.60x current ratio provides a solid financial cushion.
BIAFW Profitability Ratios
BIAFW vs Healthcare Sector
How bioAffinity Technologies, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BIAFW Balance Sheet & Liquidity
BIAFW 5-Year Financial Trend
5-Year Trend Summary: bioAffinity Technologies, Inc.'s revenue has grown significantly by 194,820% over the 5-year period, indicating strong business expansion. The most recent EPS of $-22.50 indicates the company is currently unprofitable.
BIAFW Growth Metrics (YoY)
BIAFW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.4M | -$2.0M | $-4.74 |
| Q2 2025 | $1.3M | -$2.1M | $-0.17 |
| Q1 2025 | $1.9M | -$2.0M | $-0.16 |
| Q3 2024 | $298.5K | -$2.0M | $-0.16 |
| Q2 2024 | $19.7K | -$1.7M | $-0.19 |
| Q1 2024 | $921 | -$1.5M | $-0.18 |
| Q3 2023 | $1.2K | -$2.3M | $-0.26 |
| Q2 2023 | $1.3K | -$88.1K | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BIAFW Capital Allocation
BIAFW SEC Filings
Access official SEC EDGAR filings for bioAffinity Technologies, Inc. (CIK: 0001712762)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BIAFW
What is the AI rating for BIAFW?
bioAffinity Technologies, Inc. (BIAFW) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BIAFW's key strengths?
Positive current ratio of 2.60x indicates short-term liquidity to fund operations. Zero long-term debt reduces financial leverage risk.
What are the risks of investing in BIAFW?
Revenue declining sharply at -34.2% YoY indicating loss of market traction or customer base. Negative free cash flow of -9.4M with burn rate unsustainable; cash will deplete in 6-8 quarters at current burn.
What is BIAFW's revenue and growth?
bioAffinity Technologies, Inc. reported revenue of $6.2M.
Does BIAFW pay dividends?
bioAffinity Technologies, Inc. does not currently pay dividends.
Where can I find BIAFW SEC filings?
Official SEC filings for bioAffinity Technologies, Inc. (CIK: 0001712762) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BIAFW's EPS?
bioAffinity Technologies, Inc. has a diluted EPS of $-8.66.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.